ELI LILLY AND COMPANY Other than Temporary Impairment Losses, Investments
ELI LILLY AND COMPANY (LLY) reported Other than Temporary Impairment Losses, Investments of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2020-05-01
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for the quarter ending 2019-03-31 was $0.00.
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for the quarter ending 2018-12-31 was $0.00.
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for the quarter ending 2018-09-30 was $0.00.
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for the quarter ending 2018-06-30 was $0.00.
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for fiscal 2019 was $0.00.
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for fiscal 2018 was $0.00.
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for fiscal 2017 was $0.00.
- ELI LILLY AND COMPANY other than temporary impairment losses, investments for fiscal 2015 was $42.60M, a 240.80% increase from fiscal 2014.
| Period end | Other than Temporary Impairment Losses, Investments 3 month | Other than Temporary Impairment Losses, Investments 6 month | Other than Temporary Impairment Losses, Investments 9 month | Other than Temporary Impairment Losses, Investments 12 month | Other than Temporary Impairment Losses, Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-19 | ||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-01 | $0.00 derived: sum of 2 quarters · filed 2020-05-01 | $0.00 derived: sum of 3 quarters · filed 2020-05-01 | $0.00 derived: sum of 4 quarters · filed 2020-05-01 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $0.00 derived: sum of 2 quarters · filed 2020-02-19 | $0.00 derived: sum of 3 quarters · filed 2020-02-19 | $0.00 10-K · filed 2020-02-19 | |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-25 | $0.00 derived: sum of 2 quarters · filed 2019-10-25 | $0.00 10-Q · filed 2019-10-25 | $0.00 derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-02 | $0.00 10-Q · filed 2019-08-02 | $0.00 derived: sum of 3 quarters · filed 2020-02-19 | $0.00 derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-02 | $0.00 derived: sum of 2 quarters · filed 2020-02-19 | $0.00 derived: sum of 3 quarters · filed 2020-02-19 | $0.00 derived: sum of 4 quarters · filed 2020-02-19 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $0.00 derived: sum of 2 quarters · filed 2020-02-19 | $0.00 derived: sum of 3 quarters · filed 2020-02-19 | $0.00 10-K · filed 2020-02-19 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | $0.00 derived: sum of 4 quarters · filed 2019-10-24 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-07-25 | $0.00 10-Q · filed 2018-07-25 | $0.00 derived: sum of 3 quarters · filed 2019-10-24 | $11.40M derived: sum of 4 quarters · filed 2019-10-24 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-04-27 | $0.00 derived: sum of 2 quarters · filed 2019-10-24 | $11.40M derived: sum of 3 quarters · filed 2019-10-24 | $27.30M derived: sum of 4 quarters · filed 2019-10-24 | |
| 2016-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | $11.40M derived: sum of 2 quarters · filed 2019-10-24 | $27.30M derived: sum of 3 quarters · filed 2019-10-24 | $53.00M 8-K · filed 2019-10-24 | |
| 2016-09-30 | $11.40M 10-Q · filed 2017-10-27 | $27.30M derived: sum of 2 quarters · filed 2017-10-27 | $53.00M 10-Q · filed 2017-10-27 | $54.30M derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-06-30 | $15.90M 10-Q · filed 2017-07-28 | $41.60M 10-Q · filed 2017-07-28 | $42.90M derived: sum of 3 quarters · filed 2018-02-20 | $74.40M derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-03-31 | $25.70M 10-Q · filed 2017-05-01 | $27.00M derived: sum of 2 quarters · filed 2018-02-20 | $58.50M derived: sum of 3 quarters · filed 2018-02-20 | $64.70M derived: sum of 4 quarters · filed 2018-02-20 | |
| 2015-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $32.80M derived: sum of 2 quarters · filed 2018-02-20 | $39.00M derived: sum of 3 quarters · filed 2018-02-20 | $42.60M 10-K · filed 2018-02-20 | |
| 2015-09-30 | $31.50M 10-Q · filed 2016-10-28 | $37.70M derived: sum of 2 quarters · filed 2016-10-28 | $41.30M 10-Q · filed 2016-10-28 | $42.80M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-06-30 | $6.20M 10-Q · filed 2016-07-28 | $9.80M 10-Q · filed 2016-07-28 | $11.30M derived: sum of 3 quarters · filed 2017-02-21 | $14.90M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-03-31 | $3.60M 10-Q · filed 2016-04-29 | $5.10M derived: sum of 2 quarters · filed 2017-02-21 | $8.70M derived: sum of 3 quarters · filed 2017-02-21 | $16.10M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2014-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $5.10M derived: sum of 2 quarters · filed 2017-02-21 | $12.50M derived: sum of 3 quarters · filed 2017-02-21 | $12.50M 10-K · filed 2017-02-21 | |
| 2014-09-30 | $3.60M 10-Q · filed 2015-10-30 | $11.00M derived: sum of 2 quarters · filed 2015-10-30 | $11.00M 10-Q · filed 2015-10-30 | $17.10M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $7.40M 10-Q · filed 2015-07-30 | $7.40M 10-Q · filed 2015-07-30 | $13.50M derived: sum of 3 quarters · filed 2016-02-19 | $13.50M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $0.00 10-Q · filed 2015-04-30 | $6.10M derived: sum of 2 quarters · filed 2016-02-19 | $6.10M derived: sum of 3 quarters · filed 2016-02-19 | $6.10M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2013-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $6.10M derived: sum of 2 quarters · filed 2016-02-19 | $6.10M derived: sum of 3 quarters · filed 2016-02-19 | $11.30M 10-K · filed 2016-02-19 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-10-29 | $0.00 derived: sum of 2 quarters · filed 2014-10-29 | $5.20M 10-Q · filed 2014-10-29 | $19.60M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-07-28 | $5.20M 10-Q · filed 2014-07-28 | $19.60M derived: sum of 3 quarters · filed 2015-02-19 | $20.40M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-03-31 | $5.20M 10-Q · filed 2014-04-28 | $19.60M derived: sum of 2 quarters · filed 2015-02-19 | $20.40M derived: sum of 3 quarters · filed 2015-02-19 | $24.10M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2012-12-31 | $14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $15.20M derived: sum of 2 quarters · filed 2015-02-19 | $18.90M derived: sum of 3 quarters · filed 2015-02-19 | $22.60M 10-K · filed 2015-02-19 | $12.20M 10-K · filed 2013-02-21 |
| 2012-09-30 | $800.00K 10-Q · filed 2013-10-30 | $4.50M derived: sum of 2 quarters · filed 2013-10-30 | $8.20M 10-Q · filed 2013-10-30 | $21.40M derived: sum of 4 quarters · filed 2014-02-19 | |
| 2012-06-30 | $3.70M 10-Q · filed 2013-07-26 | $7.40M 10-Q · filed 2013-07-26 | $20.60M derived: sum of 3 quarters · filed 2014-02-19 | $31.50M derived: sum of 4 quarters · filed 2014-02-19 | |
| 2012-03-31 | $3.70M 10-Q · filed 2013-04-26 | $16.90M derived: sum of 2 quarters · filed 2014-02-19 | $27.80M derived: sum of 3 quarters · filed 2014-02-19 | $34.40M derived: sum of 4 quarters · filed 2014-02-19 | |
| 2011-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $24.10M derived: sum of 2 quarters · filed 2014-02-19 | $30.70M derived: sum of 3 quarters · filed 2014-02-19 | $31.10M 10-K · filed 2014-02-19 | $26.80M 10-K · filed 2012-02-24 |
| 2011-09-30 | $10.90M 10-Q · filed 2012-10-26 | $17.50M derived: sum of 2 quarters · filed 2012-10-26 | $17.90M 10-Q · filed 2012-10-26 | $18.60M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-06-30 | $6.60M 10-Q · filed 2012-07-27 | $7.10M 10-Q · filed 2012-07-27 | $7.70M derived: sum of 3 quarters · filed 2013-02-21 | $12.40M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-03-31 | $500.00K 10-Q · filed 2012-04-30 | $1.10M derived: sum of 2 quarters · filed 2013-02-21 | $5.80M derived: sum of 3 quarters · filed 2013-02-21 | $11.50M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2010-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $5.30M derived: sum of 2 quarters · filed 2013-02-21 | $11.00M derived: sum of 3 quarters · filed 2013-02-21 | $12.00M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $4.70M 10-Q · filed 2011-10-28 | $10.40M derived: sum of 2 quarters · filed 2011-10-28 | $11.40M 10-Q · filed 2011-10-28 | $15.50M derived: sum of 4 quarters · filed 2012-02-24 | |
| 2010-06-30 | $5.70M 10-Q · filed 2011-07-29 | $6.70M 10-Q · filed 2011-07-29 | $10.80M derived: sum of 3 quarters · filed 2012-02-24 | $21.50M derived: sum of 4 quarters · filed 2012-02-24 | |
| 2010-03-31 | $1.00M 10-Q · filed 2011-04-29 | $5.10M derived: sum of 2 quarters · filed 2012-02-24 | $15.80M derived: sum of 3 quarters · filed 2012-02-24 | $18.10M derived: sum of 4 quarters · filed 2012-02-24 | |
| 2009-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $14.80M derived: sum of 2 quarters · filed 2012-02-24 | $17.10M derived: sum of 3 quarters · filed 2012-02-24 | $22.40M 10-K · filed 2012-02-24 | |
| 2009-09-30 | $10.70M 10-Q · filed 2010-10-29 | $13.00M derived: sum of 2 quarters · filed 2010-10-29 | $18.30M 10-Q · filed 2010-10-29 | ||
| 2009-06-30 | $2.30M 10-Q/A · filed 2010-08-02 | $7.60M 10-Q/A · filed 2010-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |